LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Uždarymo kaina

SektoriusSveikatos priežiūra

13.31 -2.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.1

Max

13.83

Pagrindiniai rodikliai
By Trading Economics
Pajamos	6.8M -12M
Pardavimai	-1.5M 17M
Pelno marža	-64.131
Darbuotojai	120
EBITDA	-16M -24M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+42.43% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	27M 449M
Ankstesnė atidarymo kaina	15.51
Ankstesnė uždarymo kaina	13.31

Naujienos nuotaikos

By Acuity

75%

25%

319 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

5.04 / 5.44 Palaikymas ir pasipriešinimas

ENANTA PHARMACEUTICALS INC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-15 16:02; UTC

Uždarbis

Pagrindinės rinkos jėgos

Forward Industries Shares Fall on New Debt as Solana Value Drops

2026-05-15 14:55; UTC

Pagrindinės rinkos jėgos

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

2026-05-15 14:43; UTC

Pagrindinės rinkos jėgos

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-15 17:28; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

2026-05-15 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

2026-05-15 16:24; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

2026-05-15 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 15:55; UTC

Rinkos pokalbiai

Canada's 1Q Rebound Not a Turning Point -- Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Silver Plunges on Inflation Worries -- Market Talk

2026-05-15 15:20; UTC

Uždarbis

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

2026-05-15 14:33; UTC

Rinkos pokalbiai

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Akcijų palyginimas

Kainos pokytis

ENANTA PHARMACEUTICALS INC Prognozė

Kainos tikslas

By TipRanks

42.43% į viršų

12 mėnesių prognozė

Vidutinis 19.67 USD 42.43%

Aukščiausias 20 USD

Žemiausias 19 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ENANTA PHARMACEUTICALS INC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių ENANTA PHARMACEUTICALS INC akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

5.04 / 5.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

319 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.